ArticleInternational urology and nephrology2026
Role of neoadjuvant chemotherapy in micropapillary urothelial carcinoma: a multi-institutional analysis from the Korean Bladder Cancer Research Group.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe evaluated the association of neoadjuvant chemotherapy (NAC) with pathological downstaging and overall survival (OS) in patients with micropapillary urothelial carcinoma (MPUC) in a multi-institutional cohort.
methodsWe retrospectively analysed patients who underwent radical cystectomy for muscle-invasive bladder cancer between 2003 and 2024. Patients were classified as having pure urothelial carcinoma (UC) or MPUC, and baseline clinicopathological characteristics were compared between the groups. The primary endpoint was complete pathological response (pT0N0; ypT0N0 in NAC-treated patients) and the secondary endpoint was OS, evaluated using logistic regression, Kaplan-Meier, and Cox proportional-hazards analyses.
resultsAmongst 1634 patients, 88 (5.4%) had MPUC. NAC was administered to 26.6% of patients with pure UC and 23.9% of those with MPUC. The pT0N0 rate was higher with NAC in both groups (pure UC, 22.4% vs 8.0%; MPUC, 33.3% vs 6.0%). NAC was independently associated with pT0N0 in the pure UC group (odds ratio [OR] 3.36, 95% confidence interval [CI] 2.42-4.65) and, on univariable analysis, in the MPUC group (OR 7.87, 95% CI 2.02-30.62). However, OS did not differ significantly by NAC status in either subtype (log-rank P = 0.426 and P = 0.281), and MPUC histology was not independently associated with OS after multivariable adjustment (adjusted hazard ratio 0.87, 95% CI 0.61-1.25). The number of MPUC patients achieving pT0N0 was small (n = 11), limiting the statistical power of the survival analyses.
conclusionNeoadjuvant chemotherapy was associated with a higher pathological complete response rate in micropapillary urothelial carcinoma; however, whether this translates into an OS benefit remains unclear based on the available survival data. These survival findings should be regarded as exploratory and hypothesis-generating.
Indexed as
Identifiers
42821182What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.